75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)

D Planchard,L Paz-Ares,A Spira,E Felip,S Mccune,T Cascella,J Dennie,P Bhagavatheeswaran,C Dumitru,H Borghaei

doi:10.1016/s1556-0864(23)00329-5

75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)

D Planchard, L Paz-Ares + Show 8 more

Open Access

https://doi.org/10.1016/s1556-0864(23)00329-5

Copy DOI

Journal: Journal of Thoracic Oncology	Publication Date: Apr 1, 2023
Citations: 1	License type: publisher-specific-oa

Affiliation: Institut Gustave Roussy, Universidad Complutense de Madrid, Virginia Cancer Specialists, Vall d'Hebron Institute of Oncology, Northwest Behavioral Medicine, Bristol-Myers Squibb (United States), Eisai (United States), Fox Chase Cancer Center

#Metastatic Non-small Cell Lung Cancer #Non-small Cell Lung Cancer Adenocarcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)

Full Text